Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade

被引:3
|
作者
Beatrici, Edoardo [1 ,2 ,3 ,4 ]
Filipas, Dejan K. [2 ,3 ,5 ]
Stone, Benjamin, V [2 ,3 ]
Labban, Muhieddine [2 ,3 ]
Qian, Zhiyu [2 ,3 ]
Lipsitz, Stuart R. [2 ,3 ,6 ]
Lughezzani, Giovanni [1 ,4 ]
Buffi, Nicolo M. [1 ,4 ]
Cole, Alexander P. [2 ,3 ]
Trinh, Quoc-Dien [2 ,3 ]
机构
[1] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[2] Harvard Med Sch, Brigham & Womens Hosp, Div Urol Surg, Boston, MA 02115 USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA
[4] IRCCS, Humanitas Res Hosp, Dept Urol, Milan, Italy
[5] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[6] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA
关键词
COVID-19; Grade; Migration; Prostate cancer; Screening; Stage; DIGITAL RECTAL EXAMINATION; SCREENING TRIAL; OVERTREATMENT; MORTALITY; LUNG; CARE;
D O I
10.1016/j.urolonc.2023.09.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Early 2010s data suggest a reverse stage and grade migration towards more aggressive prostate cancer (PCa) at diagnosis, accelerated by the 2012 US Preventive Services Task Force recommendation against PSA screening. Using the National Cancer Database, we investigated the impact of the 2018 USPSTF recommendation and the COVID-19 outbreak on this shift. We hypothesized that the COVID-19 outbreak would further contribute to a stage and grade migration towards more aggressive disease.Material and methods: We identified men with localized PCa diagnosed between 2010 and 2020. We analyzed the shift in the proportion of PCa stratified according to D'Amico risk classification. We used multivariable logistic regression models to assess the association between year of diagnosis and dichotomous variables related to clinical stage and grade of PCa. Predicted probabilities with 95% CI were computed through marginal effect analyses.Results: We identified 910,898 men with localized PCa. The proportion of low-risk PCa almost halved from 34.9% in 2010 to 17.7% in 2020 (P < 0.001). Compared to 2010, we found in each year increased odds of: PSA >= 10 ng/dL starting from 2012 (aOR2012 1.05; 95% CI, 1.02-1.08); cT3-T4 starting from 2015 (aOR2015 1.10; 95% CI, 1.03-1.17); ISUP GG 3-5 starting from 2011 (aOR2011 1.06; 95% CI, 1.03-1.08); and consequently, D'Amico intermediate/high-risk class starting from 2011 (aOR2011 1.03; 95% CI, 1.01-1.05). Fluctuations in the probabilities of PSA >= 10 ng/dL and cT3-T4 at diagnosis were observed over time (all P < 0.001). The probability of PSA >= 10 ng/dL peaked at 29.0% (95% CI, 28.0%-29.0%) in 2018, while the probability of cT3-T4 peaked at 3.7% (95% CI, 3.6%-3.8%) in 2020. All other outcome variables demonstrated a consistent upward shift (all P < 0.001), with the highest probabilities in 2020 for ISUP GG 3-5 (42.3%, 95% CI, 41.9%-42.6%) and D'Amico intermediate/high-risk (81.3%, 95% CI, 81.0%-81.6%).Conclusions: Our study confirms an enduring shift towards a higher proportion of aggressive PCa at diagnosis, likely influenced by the COVID-19 pandemic. The impact of the 2018 USPSTF PCa screening recommendation on the proportion of aggressive PCa seems restricted and likely affected by the pandemic outbreak. Future investigations should evaluate the long-term effects of the 2018 USPSTF recommendations in the postpandemic setting.(c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:483.e11 / 483.e19
页数:9
相关论文
共 50 条
  • [1] Grade Migration of Prostate Cancer in the United States During the Last Decade
    Borregales, Leonardo D.
    DeMeo, Gina
    Gu, Xiangmei
    Cheng, Emily
    Dudley, Vanessa
    Schaeffer, Edward M.
    Nagar, Himanshu
    Carlsson, Sigrid
    Vickers, Andrew
    Hu, Jim C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (07): : 1012 - 1019
  • [2] Re: Grade Migration of Prostate Cancer in the United States During the Last Decade
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2022, 208 (06): : 1350 - 1350
  • [3] RE: Grade Migration of Prostate Cancer in the United States During the Last Decade
    Takahashi, Takeshi
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (11): : 1553 - 1554
  • [4] Stage migration in clinically localized prostate cancer
    Noldus, J
    Graefen, M
    Haese, A
    Henke, RP
    Hammerer, P
    Huland, H
    EUROPEAN UROLOGY, 2000, 38 (01) : 74 - 78
  • [5] STAGE AND GRADE MIGRATION OF PROSTATE CANCER DURING THE COVID-19 PANDEMIC
    Beatrici, Edoardo
    Labban, Muhieddine
    Stone, Benjamin V.
    Filipas, Dejan K.
    Frego, Nicola
    Voleti, Sandeep S.
    Buffi, Nicolo Maria
    Lughezzani, Giovanni
    Abdollah, Firas
    Kibel, Adam S.
    Cole, Alexander P.
    Trinh, Quoc-Dien
    JOURNAL OF UROLOGY, 2023, 209 : E1105 - E1106
  • [6] Inaccuracies in Assignment of Clinical Stage for Localized Prostate Cancer
    Reese, Adam C.
    Sadetsky, Natalia
    Carroll, Peter R.
    Cooperberg, Matthew R.
    CANCER, 2011, 117 (02) : 283 - 289
  • [7] Contemporary grading and staging impact on grade and stage migration in prostate cancer
    Moscovita, Falzarano S.
    Zhou, M.
    Klein, E.
    Galluzzi, Magi C.
    VIRCHOWS ARCHIV, 2009, 455 : 141 - 141
  • [8] The effect of age at diagnosis on prostate cancer mortality: A grade-for-grade and stage-for-stage analysis
    Gandaglia, G.
    Karakiewicz, P. I.
    Abdollah, F.
    Becker, A.
    Roghmann, F.
    Sammon, J. D.
    Kim, S. P.
    Perrotte, P.
    Briganti, A.
    Montorsi, F.
    Trinh, Q. -D.
    Sun, M.
    EJSO, 2014, 40 (12): : 1706 - 1715
  • [9] THE EFFECT OF AGE AT DIAGNOSIS ON PROSTATE CANCER MORTALITY: A GRADE-FOR-GRADE AND STAGE-FOR-STAGE ANALYSIS
    Gandaglia, Giorgio
    Abdollah, Firas
    Schiffmann, Jonas
    Roghmann, Florian
    Becker, Andreas
    Trudeau, Vincent
    Perrotte, Paul
    Briganti, Alberto
    Montorsi, Francesco
    Karakiewicz, Pierre I.
    Trinh, Quoc-Dien
    Sun, Maxine
    JOURNAL OF UROLOGY, 2014, 191 (04): : E347 - E348
  • [10] Grade Migration of Prostate Cancer in the United States During the Last Decade (vol 114 , djac145, 2022)
    不详
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (01): : 115 - 115